nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—Folic Acid Metabolism Inhibitors—Pemetrexed—lung cancer	0.271	1	CiPCiCtD
Methotrexate—Pemetrexed—lung cancer	0.184	1	CrCtD
Methotrexate—esophageal cancer—lung cancer	0.0379	0.264	CtDrD
Methotrexate—colon cancer—lung cancer	0.0317	0.221	CtDrD
Methotrexate—ABCC3—lung cancer	0.0312	0.371	CbGaD
Methotrexate—ATIC—Pemetrexed—lung cancer	0.0307	0.234	CbGbCtD
Methotrexate—bone cancer—lung cancer	0.0272	0.19	CtDrD
Methotrexate—TYMS—lung cancer	0.0249	0.296	CbGaD
Methotrexate—Raltitrexed—Pemetrexed—lung cancer	0.0245	0.2	CrCrCtD
Methotrexate—Tetrahydrofolic acid—Pemetrexed—lung cancer	0.0245	0.2	CrCrCtD
Methotrexate—Leucovorin—Pemetrexed—lung cancer	0.0245	0.2	CrCrCtD
Methotrexate—Folic Acid—Pemetrexed—lung cancer	0.0245	0.2	CrCrCtD
Methotrexate—Pralatrexate—Pemetrexed—lung cancer	0.0245	0.2	CrCrCtD
Methotrexate—SLC46A1—Pemetrexed—lung cancer	0.0244	0.186	CbGbCtD
Methotrexate—muscle cancer—lung cancer	0.0241	0.168	CtDrD
Methotrexate—testicular cancer—lung cancer	0.0226	0.157	CtDrD
Methotrexate—DHFR—Pemetrexed—lung cancer	0.0156	0.119	CbGbCtD
Methotrexate—ABCG2—lung cancer	0.0152	0.18	CbGaD
Methotrexate—TYMS—Pemetrexed—lung cancer	0.0108	0.0828	CbGbCtD
Methotrexate—ALB—lung cancer	0.00661	0.0785	CbGaD
Methotrexate—ABCB1—lung cancer	0.00631	0.075	CbGaD
Methotrexate—TYMS—Gemcitabine—lung cancer	0.00391	0.0298	CbGbCtD
Methotrexate—ABCC10—Gemcitabine—lung cancer	0.00322	0.0246	CbGbCtD
Methotrexate—ABCC10—Paclitaxel—lung cancer	0.00291	0.0222	CbGbCtD
Methotrexate—ABCC10—Etoposide—lung cancer	0.0023	0.0175	CbGbCtD
Methotrexate—ABCC10—Docetaxel—lung cancer	0.0021	0.0161	CbGbCtD
Methotrexate—SLCO1B3—Paclitaxel—lung cancer	0.00163	0.0124	CbGbCtD
Methotrexate—ABCC10—Doxorubicin—lung cancer	0.00157	0.012	CbGbCtD
Methotrexate—ABCG2—Topotecan—lung cancer	0.00152	0.0116	CbGbCtD
Methotrexate—ABCC3—Cisplatin—lung cancer	0.00147	0.0112	CbGbCtD
Methotrexate—ABCC3—Etoposide—lung cancer	0.00145	0.011	CbGbCtD
Methotrexate—ABCG2—Gefitinib—lung cancer	0.00139	0.0106	CbGbCtD
Methotrexate—ABCG2—Teniposide—lung cancer	0.00135	0.0103	CbGbCtD
Methotrexate—SLCO1B3—Docetaxel—lung cancer	0.00117	0.00896	CbGbCtD
Methotrexate—ABCC1—Paclitaxel—lung cancer	0.00112	0.00857	CbGbCtD
Methotrexate—ABCC1—Irinotecan—lung cancer	0.00111	0.00846	CbGbCtD
Methotrexate—SLC22A7—Docetaxel—lung cancer	0.00103	0.00789	CbGbCtD
Methotrexate—ABCC3—Doxorubicin—lung cancer	0.000986	0.00752	CbGbCtD
Methotrexate—ABCC1—Vinblastine—lung cancer	0.000985	0.00752	CbGbCtD
Methotrexate—ALB—Gefitinib—lung cancer	0.000958	0.00731	CbGbCtD
Methotrexate—SLCO1B1—Irinotecan—lung cancer	0.000934	0.00712	CbGbCtD
Methotrexate—ABCC1—Etoposide—lung cancer	0.000888	0.00677	CbGbCtD
Methotrexate—ABCC2—Paclitaxel—lung cancer	0.000832	0.00634	CbGbCtD
Methotrexate—ABCG2—Erlotinib—lung cancer	0.000821	0.00627	CbGbCtD
Methotrexate—ABCC2—Irinotecan—lung cancer	0.00082	0.00626	CbGbCtD
Methotrexate—ABCC1—Docetaxel—lung cancer	0.000812	0.0062	CbGbCtD
Methotrexate—ABCG2—Paclitaxel—lung cancer	0.000752	0.00574	CbGbCtD
Methotrexate—ABCG2—Irinotecan—lung cancer	0.000742	0.00566	CbGbCtD
Methotrexate—ABCC2—Vinblastine—lung cancer	0.000729	0.00556	CbGbCtD
Methotrexate—ABCC2—Cisplatin—lung cancer	0.000669	0.0051	CbGbCtD
Methotrexate—ABCC2—Etoposide—lung cancer	0.000657	0.00501	CbGbCtD
Methotrexate—ABCC1—Doxorubicin—lung cancer	0.000605	0.00462	CbGbCtD
Methotrexate—ABCG2—Cisplatin—lung cancer	0.000605	0.00461	CbGbCtD
Methotrexate—ABCC2—Docetaxel—lung cancer	0.000601	0.00459	CbGbCtD
Methotrexate—ABCG2—Etoposide—lung cancer	0.000594	0.00453	CbGbCtD
Methotrexate—ALB—Erlotinib—lung cancer	0.000566	0.00432	CbGbCtD
Methotrexate—ABCB1—Topotecan—lung cancer	0.000548	0.00418	CbGbCtD
Methotrexate—ABCG2—Docetaxel—lung cancer	0.000544	0.00415	CbGbCtD
Methotrexate—ALB—Irinotecan—lung cancer	0.000511	0.0039	CbGbCtD
Methotrexate—ABCB1—Gefitinib—lung cancer	0.000501	0.00382	CbGbCtD
Methotrexate—FOLR1—mammary gland—lung cancer	0.000486	0.0462	CbGeAlD
Methotrexate—ABCC11—mammary gland—lung cancer	0.000466	0.0443	CbGeAlD
Methotrexate—ABCC2—Doxorubicin—lung cancer	0.000448	0.00342	CbGbCtD
Methotrexate—SLC19A1—mammary gland—lung cancer	0.000426	0.0405	CbGeAlD
Methotrexate—ABCG2—Doxorubicin—lung cancer	0.000405	0.00309	CbGbCtD
Methotrexate—ABCB1—Vinorelbine—lung cancer	0.000386	0.00294	CbGbCtD
Methotrexate—FOLR1—respiratory system—lung cancer	0.000324	0.0308	CbGeAlD
Methotrexate—ABCB1—Crizotinib—lung cancer	0.000307	0.00234	CbGbCtD
Methotrexate—ABCB1—Gemcitabine—lung cancer	0.0003	0.00229	CbGbCtD
Methotrexate—ABCB1—Erlotinib—lung cancer	0.000296	0.00226	CbGbCtD
Methotrexate—ATIC—mammary gland—lung cancer	0.000275	0.0261	CbGeAlD
Methotrexate—ABCB1—Paclitaxel—lung cancer	0.000271	0.00207	CbGbCtD
Methotrexate—FOLR1—epithelium—lung cancer	0.000271	0.0257	CbGeAlD
Methotrexate—ABCB1—Irinotecan—lung cancer	0.000267	0.00204	CbGbCtD
Methotrexate—FOLR1—bronchus—lung cancer	0.000267	0.0253	CbGeAlD
Methotrexate—FOLR1—trachea—lung cancer	0.00024	0.0227	CbGeAlD
Methotrexate—ABCB1—Vinblastine—lung cancer	0.000238	0.00181	CbGbCtD
Methotrexate—ABCB1—Cisplatin—lung cancer	0.000218	0.00166	CbGbCtD
Methotrexate—ABCB1—Etoposide—lung cancer	0.000214	0.00163	CbGbCtD
Methotrexate—MTHFR—mammary gland—lung cancer	0.000204	0.0194	CbGeAlD
Methotrexate—ABCB1—Docetaxel—lung cancer	0.000196	0.0015	CbGbCtD
Methotrexate—FPGS—respiratory system—lung cancer	0.000189	0.018	CbGeAlD
Methotrexate—ATIC—respiratory system—lung cancer	0.000183	0.0174	CbGeAlD
Methotrexate—PGD—mammary gland—lung cancer	0.000177	0.0168	CbGeAlD
Methotrexate—GGH—bronchus—lung cancer	0.000177	0.0168	CbGeAlD
Methotrexate—FOLR1—lung—lung cancer	0.000172	0.0163	CbGeAlD
Methotrexate—SLCO1B1—mammary gland—lung cancer	0.000161	0.0153	CbGeAlD
Methotrexate—GGH—trachea—lung cancer	0.000159	0.0151	CbGeAlD
Methotrexate—FPGS—bronchus—lung cancer	0.000156	0.0148	CbGeAlD
Methotrexate—ATIC—epithelium—lung cancer	0.000153	0.0145	CbGeAlD
Methotrexate—Raltitrexed—TYMS—lung cancer	0.000152	0.192	CrCbGaD
Methotrexate—SLC19A1—lung—lung cancer	0.000151	0.0143	CbGeAlD
Methotrexate—ABCB1—Doxorubicin—lung cancer	0.000146	0.00111	CbGbCtD
Methotrexate—Leucovorin—ABCC3—lung cancer	0.000145	0.182	CrCbGaD
Methotrexate—SLCO4C1—trachea—lung cancer	0.000141	0.0134	CbGeAlD
Methotrexate—FPGS—trachea—lung cancer	0.00014	0.0133	CbGeAlD
Methotrexate—MTHFR—respiratory system—lung cancer	0.000136	0.0129	CbGeAlD
Methotrexate—FPGS—cardiac atrium—lung cancer	0.000131	0.0125	CbGeAlD
Methotrexate—ALB—mammary gland—lung cancer	0.00013	0.0124	CbGeAlD
Methotrexate—GGH—bone marrow—lung cancer	0.000126	0.012	CbGeAlD
Methotrexate—TYMS—respiratory system—lung cancer	0.000124	0.0118	CbGeAlD
Methotrexate—DHFR—respiratory system—lung cancer	0.000123	0.0117	CbGeAlD
Methotrexate—PGD—respiratory system—lung cancer	0.000118	0.0112	CbGeAlD
Methotrexate—Pralatrexate—TYMS—lung cancer	0.000115	0.145	CrCbGaD
Methotrexate—Leucovorin—TYMS—lung cancer	0.000115	0.145	CrCbGaD
Methotrexate—GGH—lung—lung cancer	0.000114	0.0109	CbGeAlD
Methotrexate—MTHFR—bronchus—lung cancer	0.000112	0.0106	CbGeAlD
Methotrexate—SLCO4C1—bone marrow—lung cancer	0.000112	0.0106	CbGeAlD
Methotrexate—SLCO3A1—bronchus—lung cancer	0.00011	0.0105	CbGeAlD
Methotrexate—SLC19A1—lymph node—lung cancer	0.000103	0.0098	CbGeAlD
Methotrexate—TYMS—bronchus—lung cancer	0.000102	0.00971	CbGeAlD
Methotrexate—ABCC3—respiratory system—lung cancer	0.000102	0.00967	CbGeAlD
Methotrexate—SLCO4C1—lung—lung cancer	0.000101	0.00963	CbGeAlD
Methotrexate—DHFR—bronchus—lung cancer	0.000101	0.00961	CbGeAlD
Methotrexate—FPGS—lung—lung cancer	0.000101	0.00955	CbGeAlD
Methotrexate—SLCO1B3—lung—lung cancer	9.86e-05	0.00936	CbGeAlD
Methotrexate—PGD—bronchus—lung cancer	9.73e-05	0.00924	CbGeAlD
Methotrexate—ATIC—lung—lung cancer	9.73e-05	0.00923	CbGeAlD
Methotrexate—Folic Acid—ABCC3—lung cancer	9.33e-05	0.117	CrCbGaD
Methotrexate—SLCO3A1—cardiac atrium—lung cancer	9.3e-05	0.00883	CbGeAlD
Methotrexate—Pemetrexed—TYMS—lung cancer	9.23e-05	0.116	CrCbGaD
Methotrexate—SLC16A1—epithelium—lung cancer	9.22e-05	0.00876	CbGeAlD
Methotrexate—DHFR—trachea—lung cancer	9.09e-05	0.00863	CbGeAlD
Methotrexate—TYMS—Docetaxel—Paclitaxel—lung cancer	9.07e-05	0.185	CbGdCrCtD
Methotrexate—PGD—trachea—lung cancer	8.74e-05	0.0083	CbGeAlD
Methotrexate—AOX1—bronchus—lung cancer	8.57e-05	0.00814	CbGeAlD
Methotrexate—DHFR—cardiac atrium—lung cancer	8.54e-05	0.00811	CbGeAlD
Methotrexate—ABCC10—bronchus—lung cancer	8.34e-05	0.00792	CbGeAlD
Methotrexate—PGD—cardiac atrium—lung cancer	8.21e-05	0.00779	CbGeAlD
Methotrexate—SLC46A1—lymph node—lung cancer	7.95e-05	0.00755	CbGeAlD
Methotrexate—GGH—lymph node—lung cancer	7.82e-05	0.00743	CbGeAlD
Methotrexate—AOX1—trachea—lung cancer	7.7e-05	0.00731	CbGeAlD
Methotrexate—SLC16A1—cardiac atrium—lung cancer	7.66e-05	0.00728	CbGeAlD
Methotrexate—ABCC10—trachea—lung cancer	7.49e-05	0.00711	CbGeAlD
Methotrexate—TYMS—bone marrow—lung cancer	7.28e-05	0.00691	CbGeAlD
Methotrexate—AOX1—cardiac atrium—lung cancer	7.23e-05	0.00687	CbGeAlD
Methotrexate—MTHFR—lung—lung cancer	7.23e-05	0.00686	CbGeAlD
Methotrexate—DHFR—bone marrow—lung cancer	7.21e-05	0.00684	CbGeAlD
Methotrexate—SLCO3A1—lung—lung cancer	7.11e-05	0.00675	CbGeAlD
Methotrexate—ABCC10—cardiac atrium—lung cancer	7.04e-05	0.00668	CbGeAlD
Methotrexate—PGD—bone marrow—lung cancer	6.93e-05	0.00658	CbGeAlD
Methotrexate—ABCC4—bronchus—lung cancer	6.92e-05	0.00657	CbGeAlD
Methotrexate—FPGS—lymph node—lung cancer	6.88e-05	0.00653	CbGeAlD
Methotrexate—TYMS—Erlotinib—Gefitinib—lung cancer	6.77e-05	0.138	CbGdCrCtD
Methotrexate—ATIC—lymph node—lung cancer	6.65e-05	0.00632	CbGeAlD
Methotrexate—TYMS—lung—lung cancer	6.6e-05	0.00626	CbGeAlD
Methotrexate—DHFR—lung—lung cancer	6.53e-05	0.0062	CbGeAlD
Methotrexate—PGD—lung—lung cancer	6.28e-05	0.00596	CbGeAlD
Methotrexate—ABCC10—bone marrow—lung cancer	5.94e-05	0.00564	CbGeAlD
Methotrexate—ABCC1—bronchus—lung cancer	5.9e-05	0.0056	CbGeAlD
Methotrexate—SLC16A1—lung—lung cancer	5.86e-05	0.00557	CbGeAlD
Methotrexate—AOX1—lung—lung cancer	5.53e-05	0.00525	CbGeAlD
Methotrexate—SLCO1C1—lymph node—lung cancer	5.53e-05	0.00525	CbGeAlD
Methotrexate—ABCC3—lung—lung cancer	5.41e-05	0.00514	CbGeAlD
Methotrexate—ABCC10—lung—lung cancer	5.38e-05	0.00511	CbGeAlD
Methotrexate—ABCC1—trachea—lung cancer	5.3e-05	0.00503	CbGeAlD
Methotrexate—ABCC1—cardiac atrium—lung cancer	4.98e-05	0.00473	CbGeAlD
Methotrexate—MTHFR—lymph node—lung cancer	4.94e-05	0.00469	CbGeAlD
Methotrexate—ABCC4—bone marrow—lung cancer	4.93e-05	0.00468	CbGeAlD
Methotrexate—TYMS—Podofilox—Teniposide—lung cancer	4.89e-05	0.0995	CbGdCrCtD
Methotrexate—SLCO3A1—lymph node—lung cancer	4.86e-05	0.00462	CbGeAlD
Methotrexate—SLCO1A2—lung—lung cancer	4.64e-05	0.00441	CbGeAlD
Methotrexate—Folic Acid—ABCG2—lung cancer	4.53e-05	0.057	CrCbGaD
Methotrexate—TYMS—Paclitaxel—Docetaxel—lung cancer	4.53e-05	0.0922	CbGdCrCtD
Methotrexate—TYMS—lymph node—lung cancer	4.51e-05	0.00428	CbGeAlD
Methotrexate—DHFR—lymph node—lung cancer	4.47e-05	0.00424	CbGeAlD
Methotrexate—ABCC4—lung—lung cancer	4.47e-05	0.00424	CbGeAlD
Methotrexate—TYMS—Afatinib—Gefitinib—lung cancer	4.43e-05	0.0902	CbGdCrCtD
Methotrexate—TYMS—Gefitinib—Erlotinib—lung cancer	4.34e-05	0.0884	CbGdCrCtD
Methotrexate—PGD—lymph node—lung cancer	4.29e-05	0.00408	CbGeAlD
Methotrexate—SLC16A1—lymph node—lung cancer	4.01e-05	0.00381	CbGeAlD
Methotrexate—ABCC1—lung—lung cancer	3.81e-05	0.00362	CbGeAlD
Methotrexate—AOX1—lymph node—lung cancer	3.78e-05	0.00359	CbGeAlD
Methotrexate—ABCC3—lymph node—lung cancer	3.7e-05	0.00351	CbGeAlD
Methotrexate—ABCC10—lymph node—lung cancer	3.68e-05	0.0035	CbGeAlD
Methotrexate—Folic Acid—CYP2E1—lung cancer	3.6e-05	0.0452	CrCbGaD
Methotrexate—ABCG2—bone marrow—lung cancer	3.48e-05	0.0033	CbGeAlD
Methotrexate—ALB—lymph node—lung cancer	3.15e-05	0.003	CbGeAlD
Methotrexate—ABCG2—lung—lung cancer	3.15e-05	0.00299	CbGeAlD
Methotrexate—TYMS—Vincristine—Vinorelbine—lung cancer	3.11e-05	0.0634	CbGdCrCtD
Methotrexate—ABCC4—lymph node—lung cancer	3.05e-05	0.0029	CbGeAlD
Methotrexate—ABCC2—lymph node—lung cancer	2.96e-05	0.00281	CbGeAlD
Methotrexate—ABCB1—respiratory system—lung cancer	2.93e-05	0.00278	CbGeAlD
Methotrexate—TYMS—Vinorelbine—Vinblastine—lung cancer	2.91e-05	0.0592	CbGdCrCtD
Methotrexate—TYMS—Podofilox—Etoposide—lung cancer	2.91e-05	0.0592	CbGdCrCtD
Methotrexate—ABCC1—lymph node—lung cancer	2.6e-05	0.00247	CbGeAlD
Methotrexate—TYMS—Vinblastine—Vinorelbine—lung cancer	2.5e-05	0.051	CbGdCrCtD
Methotrexate—TYMS—Vincristine—Vinblastine—lung cancer	2.49e-05	0.0507	CbGdCrCtD
Methotrexate—ABCB1—epithelium—lung cancer	2.45e-05	0.00232	CbGeAlD
Methotrexate—ABCB1—trachea—lung cancer	2.16e-05	0.00205	CbGeAlD
Methotrexate—ABCG2—lymph node—lung cancer	2.16e-05	0.00205	CbGeAlD
Methotrexate—ABCB1—bone marrow—lung cancer	1.72e-05	0.00163	CbGeAlD
Methotrexate—ABCB1—lung—lung cancer	1.55e-05	0.00148	CbGeAlD
Methotrexate—TYMS—Azacitidine—Gemcitabine—lung cancer	1.17e-05	0.0239	CbGdCrCtD
Methotrexate—ABCB1—lymph node—lung cancer	1.06e-05	0.00101	CbGeAlD
Methotrexate—Gastrointestinal disorder—Gemcitabine—lung cancer	7.3e-06	0.000235	CcSEcCtD
Methotrexate—Discomfort—Paclitaxel—lung cancer	7.3e-06	0.000234	CcSEcCtD
Methotrexate—Fatigue—Gemcitabine—lung cancer	7.29e-06	0.000234	CcSEcCtD
Methotrexate—Confusional state—Etoposide—lung cancer	7.28e-06	0.000234	CcSEcCtD
Methotrexate—Pain—Gemcitabine—lung cancer	7.23e-06	0.000232	CcSEcCtD
Methotrexate—Nausea—Erlotinib—lung cancer	7.23e-06	0.000232	CcSEcCtD
Methotrexate—Anaphylactic shock—Etoposide—lung cancer	7.22e-06	0.000232	CcSEcCtD
Methotrexate—Mood swings—Doxorubicin—lung cancer	7.22e-06	0.000232	CcSEcCtD
Methotrexate—Diarrhoea—Vinorelbine—lung cancer	7.2e-06	0.000231	CcSEcCtD
Methotrexate—Dysgeusia—Docetaxel—lung cancer	7.2e-06	0.000231	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Cisplatin—lung cancer	7.18e-06	0.000231	CcSEcCtD
Methotrexate—Infection—Etoposide—lung cancer	7.17e-06	0.00023	CcSEcCtD
Methotrexate—Ataxia—Doxorubicin—lung cancer	7.16e-06	0.00023	CcSEcCtD
Methotrexate—Feeling abnormal—Irinotecan—lung cancer	7.15e-06	0.00023	CcSEcCtD
Methotrexate—Confusional state—Paclitaxel—lung cancer	7.14e-06	0.000229	CcSEcCtD
Methotrexate—Back pain—Docetaxel—lung cancer	7.11e-06	0.000228	CcSEcCtD
Methotrexate—Gastrointestinal pain—Irinotecan—lung cancer	7.1e-06	0.000228	CcSEcCtD
Methotrexate—Anaphylactic shock—Paclitaxel—lung cancer	7.08e-06	0.000227	CcSEcCtD
Methotrexate—Paraesthesia—Cisplatin—lung cancer	7.08e-06	0.000227	CcSEcCtD
Methotrexate—Thrombocytopenia—Etoposide—lung cancer	7.07e-06	0.000227	CcSEcCtD
Methotrexate—Liver function test abnormal—Doxorubicin—lung cancer	7.03e-06	0.000226	CcSEcCtD
Methotrexate—Infection—Paclitaxel—lung cancer	7.03e-06	0.000226	CcSEcCtD
Methotrexate—Dyspnoea—Cisplatin—lung cancer	7.03e-06	0.000226	CcSEcCtD
Methotrexate—Skin disorder—Etoposide—lung cancer	7.01e-06	0.000225	CcSEcCtD
Methotrexate—Hyperhidrosis—Etoposide—lung cancer	6.98e-06	0.000224	CcSEcCtD
Methotrexate—Feeling abnormal—Gemcitabine—lung cancer	6.97e-06	0.000224	CcSEcCtD
Methotrexate—Dizziness—Vinorelbine—lung cancer	6.96e-06	0.000224	CcSEcCtD
Methotrexate—Nervous system disorder—Paclitaxel—lung cancer	6.94e-06	0.000223	CcSEcCtD
Methotrexate—Thrombocytopenia—Paclitaxel—lung cancer	6.93e-06	0.000223	CcSEcCtD
Methotrexate—Breast disorder—Doxorubicin—lung cancer	6.89e-06	0.000221	CcSEcCtD
Methotrexate—Anorexia—Etoposide—lung cancer	6.88e-06	0.000221	CcSEcCtD
Methotrexate—Skin disorder—Paclitaxel—lung cancer	6.88e-06	0.000221	CcSEcCtD
Methotrexate—Abdominal pain—Irinotecan—lung cancer	6.86e-06	0.00022	CcSEcCtD
Methotrexate—Body temperature increased—Irinotecan—lung cancer	6.86e-06	0.00022	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Doxorubicin—lung cancer	6.86e-06	0.00022	CcSEcCtD
Methotrexate—Decreased appetite—Cisplatin—lung cancer	6.85e-06	0.00022	CcSEcCtD
Methotrexate—Hyperhidrosis—Paclitaxel—lung cancer	6.84e-06	0.00022	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Cisplatin—lung cancer	6.8e-06	0.000219	CcSEcCtD
Methotrexate—Anaemia—Docetaxel—lung cancer	6.8e-06	0.000218	CcSEcCtD
Methotrexate—Anorexia—Paclitaxel—lung cancer	6.75e-06	0.000217	CcSEcCtD
Methotrexate—Hypotension—Etoposide—lung cancer	6.75e-06	0.000217	CcSEcCtD
Methotrexate—Pain—Cisplatin—lung cancer	6.74e-06	0.000217	CcSEcCtD
Methotrexate—Vomiting—Vinorelbine—lung cancer	6.69e-06	0.000215	CcSEcCtD
Methotrexate—Body temperature increased—Gemcitabine—lung cancer	6.68e-06	0.000215	CcSEcCtD
Methotrexate—Rash—Vinorelbine—lung cancer	6.64e-06	0.000213	CcSEcCtD
Methotrexate—Dermatitis—Vinorelbine—lung cancer	6.63e-06	0.000213	CcSEcCtD
Methotrexate—Hypotension—Paclitaxel—lung cancer	6.62e-06	0.000213	CcSEcCtD
Methotrexate—Headache—Vinorelbine—lung cancer	6.59e-06	0.000212	CcSEcCtD
Methotrexate—Asthma—Doxorubicin—lung cancer	6.59e-06	0.000212	CcSEcCtD
Methotrexate—Leukopenia—Docetaxel—lung cancer	6.58e-06	0.000211	CcSEcCtD
Methotrexate—Eosinophilia—Doxorubicin—lung cancer	6.52e-06	0.000209	CcSEcCtD
Methotrexate—Feeling abnormal—Cisplatin—lung cancer	6.49e-06	0.000209	CcSEcCtD
Methotrexate—Paraesthesia—Etoposide—lung cancer	6.48e-06	0.000208	CcSEcCtD
Methotrexate—Pancreatitis—Doxorubicin—lung cancer	6.46e-06	0.000207	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Paclitaxel—lung cancer	6.45e-06	0.000207	CcSEcCtD
Methotrexate—Dyspnoea—Etoposide—lung cancer	6.44e-06	0.000207	CcSEcCtD
Methotrexate—Somnolence—Etoposide—lung cancer	6.42e-06	0.000206	CcSEcCtD
Methotrexate—Cough—Docetaxel—lung cancer	6.42e-06	0.000206	CcSEcCtD
Methotrexate—Insomnia—Paclitaxel—lung cancer	6.4e-06	0.000206	CcSEcCtD
Methotrexate—Hypersensitivity—Irinotecan—lung cancer	6.4e-06	0.000205	CcSEcCtD
Methotrexate—Convulsion—Docetaxel—lung cancer	6.37e-06	0.000205	CcSEcCtD
Methotrexate—Paraesthesia—Paclitaxel—lung cancer	6.36e-06	0.000204	CcSEcCtD
Methotrexate—Dyspnoea—Paclitaxel—lung cancer	6.31e-06	0.000203	CcSEcCtD
Methotrexate—Somnolence—Paclitaxel—lung cancer	6.29e-06	0.000202	CcSEcCtD
Methotrexate—Decreased appetite—Etoposide—lung cancer	6.28e-06	0.000202	CcSEcCtD
Methotrexate—Arthralgia—Docetaxel—lung cancer	6.26e-06	0.000201	CcSEcCtD
Methotrexate—Chest pain—Docetaxel—lung cancer	6.26e-06	0.000201	CcSEcCtD
Methotrexate—Myalgia—Docetaxel—lung cancer	6.26e-06	0.000201	CcSEcCtD
Methotrexate—Pancytopenia—Doxorubicin—lung cancer	6.25e-06	0.000201	CcSEcCtD
Methotrexate—Nausea—Vinorelbine—lung cancer	6.25e-06	0.000201	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Etoposide—lung cancer	6.23e-06	0.0002	CcSEcCtD
Methotrexate—Dyspepsia—Paclitaxel—lung cancer	6.23e-06	0.0002	CcSEcCtD
Methotrexate—Body temperature increased—Cisplatin—lung cancer	6.23e-06	0.0002	CcSEcCtD
Methotrexate—Asthenia—Irinotecan—lung cancer	6.23e-06	0.0002	CcSEcCtD
Methotrexate—Fatigue—Etoposide—lung cancer	6.23e-06	0.0002	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	6.22e-06	0.0002	CcSEcCtD
Methotrexate—Pain—Etoposide—lung cancer	6.17e-06	0.000198	CcSEcCtD
Methotrexate—Dysuria—Doxorubicin—lung cancer	6.16e-06	0.000198	CcSEcCtD
Methotrexate—Neutropenia—Doxorubicin—lung cancer	6.16e-06	0.000198	CcSEcCtD
Methotrexate—Decreased appetite—Paclitaxel—lung cancer	6.15e-06	0.000198	CcSEcCtD
Methotrexate—Upper respiratory tract infection—Doxorubicin—lung cancer	6.12e-06	0.000197	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Paclitaxel—lung cancer	6.11e-06	0.000196	CcSEcCtD
Methotrexate—Fatigue—Paclitaxel—lung cancer	6.1e-06	0.000196	CcSEcCtD
Methotrexate—Asthenia—Gemcitabine—lung cancer	6.07e-06	0.000195	CcSEcCtD
Methotrexate—Pain—Paclitaxel—lung cancer	6.05e-06	0.000195	CcSEcCtD
Methotrexate—Confusional state—Docetaxel—lung cancer	6.05e-06	0.000194	CcSEcCtD
Methotrexate—Photosensitivity reaction—Doxorubicin—lung cancer	6.01e-06	0.000193	CcSEcCtD
Methotrexate—Anaphylactic shock—Docetaxel—lung cancer	6e-06	0.000193	CcSEcCtD
Methotrexate—Pruritus—Gemcitabine—lung cancer	5.98e-06	0.000192	CcSEcCtD
Methotrexate—Infection—Docetaxel—lung cancer	5.96e-06	0.000192	CcSEcCtD
Methotrexate—Feeling abnormal—Etoposide—lung cancer	5.95e-06	0.000191	CcSEcCtD
Methotrexate—Diarrhoea—Irinotecan—lung cancer	5.94e-06	0.000191	CcSEcCtD
Methotrexate—Pneumonia—Doxorubicin—lung cancer	5.91e-06	0.00019	CcSEcCtD
Methotrexate—Gastrointestinal pain—Etoposide—lung cancer	5.9e-06	0.00019	CcSEcCtD
Methotrexate—Nervous system disorder—Docetaxel—lung cancer	5.88e-06	0.000189	CcSEcCtD
Methotrexate—Thrombocytopenia—Docetaxel—lung cancer	5.88e-06	0.000189	CcSEcCtD
Methotrexate—Infestation—Doxorubicin—lung cancer	5.87e-06	0.000189	CcSEcCtD
Methotrexate—Drowsiness—Doxorubicin—lung cancer	5.87e-06	0.000189	CcSEcCtD
Methotrexate—Infestation NOS—Doxorubicin—lung cancer	5.87e-06	0.000189	CcSEcCtD
Methotrexate—Feeling abnormal—Paclitaxel—lung cancer	5.83e-06	0.000187	CcSEcCtD
Methotrexate—Skin disorder—Docetaxel—lung cancer	5.83e-06	0.000187	CcSEcCtD
Methotrexate—Stevens-Johnson syndrome—Doxorubicin—lung cancer	5.82e-06	0.000187	CcSEcCtD
Methotrexate—Hypersensitivity—Cisplatin—lung cancer	5.81e-06	0.000187	CcSEcCtD
Methotrexate—Gastrointestinal pain—Paclitaxel—lung cancer	5.79e-06	0.000186	CcSEcCtD
Methotrexate—Diarrhoea—Gemcitabine—lung cancer	5.79e-06	0.000186	CcSEcCtD
Methotrexate—Renal failure—Doxorubicin—lung cancer	5.77e-06	0.000185	CcSEcCtD
Methotrexate—Dizziness—Irinotecan—lung cancer	5.74e-06	0.000184	CcSEcCtD
Methotrexate—Urticaria—Etoposide—lung cancer	5.74e-06	0.000184	CcSEcCtD
Methotrexate—Stomatitis—Doxorubicin—lung cancer	5.72e-06	0.000184	CcSEcCtD
Methotrexate—Anorexia—Docetaxel—lung cancer	5.72e-06	0.000184	CcSEcCtD
Methotrexate—Abdominal pain—Etoposide—lung cancer	5.71e-06	0.000183	CcSEcCtD
Methotrexate—Body temperature increased—Etoposide—lung cancer	5.71e-06	0.000183	CcSEcCtD
Methotrexate—Conjunctivitis—Doxorubicin—lung cancer	5.71e-06	0.000183	CcSEcCtD
Methotrexate—Asthenia—Cisplatin—lung cancer	5.65e-06	0.000182	CcSEcCtD
Methotrexate—Sweating—Doxorubicin—lung cancer	5.63e-06	0.000181	CcSEcCtD
Methotrexate—Urticaria—Paclitaxel—lung cancer	5.62e-06	0.000181	CcSEcCtD
Methotrexate—Hypotension—Docetaxel—lung cancer	5.61e-06	0.00018	CcSEcCtD
Methotrexate—Haematuria—Doxorubicin—lung cancer	5.6e-06	0.00018	CcSEcCtD
Methotrexate—Body temperature increased—Paclitaxel—lung cancer	5.6e-06	0.00018	CcSEcCtD
Methotrexate—Abdominal pain—Paclitaxel—lung cancer	5.6e-06	0.00018	CcSEcCtD
Methotrexate—Hepatobiliary disease—Doxorubicin—lung cancer	5.55e-06	0.000178	CcSEcCtD
Methotrexate—Epistaxis—Doxorubicin—lung cancer	5.54e-06	0.000178	CcSEcCtD
Methotrexate—Vomiting—Irinotecan—lung cancer	5.52e-06	0.000177	CcSEcCtD
Methotrexate—Agranulocytosis—Doxorubicin—lung cancer	5.48e-06	0.000176	CcSEcCtD
Methotrexate—Rash—Irinotecan—lung cancer	5.47e-06	0.000176	CcSEcCtD
Methotrexate—Dermatitis—Irinotecan—lung cancer	5.47e-06	0.000176	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Docetaxel—lung cancer	5.47e-06	0.000176	CcSEcCtD
Methotrexate—Headache—Irinotecan—lung cancer	5.44e-06	0.000175	CcSEcCtD
Methotrexate—Insomnia—Docetaxel—lung cancer	5.43e-06	0.000174	CcSEcCtD
Methotrexate—Diarrhoea—Cisplatin—lung cancer	5.39e-06	0.000173	CcSEcCtD
Methotrexate—Paraesthesia—Docetaxel—lung cancer	5.39e-06	0.000173	CcSEcCtD
Methotrexate—Vomiting—Gemcitabine—lung cancer	5.38e-06	0.000173	CcSEcCtD
Methotrexate—Dyspnoea—Docetaxel—lung cancer	5.35e-06	0.000172	CcSEcCtD
Methotrexate—Somnolence—Docetaxel—lung cancer	5.33e-06	0.000171	CcSEcCtD
Methotrexate—Rash—Gemcitabine—lung cancer	5.33e-06	0.000171	CcSEcCtD
Methotrexate—Dermatitis—Gemcitabine—lung cancer	5.33e-06	0.000171	CcSEcCtD
Methotrexate—Hypersensitivity—Etoposide—lung cancer	5.32e-06	0.000171	CcSEcCtD
Methotrexate—Haemoglobin—Doxorubicin—lung cancer	5.3e-06	0.00017	CcSEcCtD
Methotrexate—Headache—Gemcitabine—lung cancer	5.3e-06	0.00017	CcSEcCtD
Methotrexate—Dyspepsia—Docetaxel—lung cancer	5.28e-06	0.00017	CcSEcCtD
Methotrexate—Haemorrhage—Doxorubicin—lung cancer	5.27e-06	0.000169	CcSEcCtD
Methotrexate—Hepatitis—Doxorubicin—lung cancer	5.27e-06	0.000169	CcSEcCtD
Methotrexate—Pharyngitis—Doxorubicin—lung cancer	5.23e-06	0.000168	CcSEcCtD
Methotrexate—Decreased appetite—Docetaxel—lung cancer	5.22e-06	0.000168	CcSEcCtD
Methotrexate—Hypersensitivity—Paclitaxel—lung cancer	5.22e-06	0.000168	CcSEcCtD
Methotrexate—Urinary tract disorder—Doxorubicin—lung cancer	5.21e-06	0.000167	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Docetaxel—lung cancer	5.18e-06	0.000166	CcSEcCtD
Methotrexate—Asthenia—Etoposide—lung cancer	5.18e-06	0.000166	CcSEcCtD
Methotrexate—Fatigue—Docetaxel—lung cancer	5.17e-06	0.000166	CcSEcCtD
Methotrexate—Urethral disorder—Doxorubicin—lung cancer	5.17e-06	0.000166	CcSEcCtD
Methotrexate—Nausea—Irinotecan—lung cancer	5.16e-06	0.000166	CcSEcCtD
Methotrexate—Pain—Docetaxel—lung cancer	5.13e-06	0.000165	CcSEcCtD
Methotrexate—Pruritus—Etoposide—lung cancer	5.11e-06	0.000164	CcSEcCtD
Methotrexate—Visual impairment—Doxorubicin—lung cancer	5.08e-06	0.000163	CcSEcCtD
Methotrexate—Asthenia—Paclitaxel—lung cancer	5.08e-06	0.000163	CcSEcCtD
Methotrexate—Nausea—Gemcitabine—lung cancer	5.02e-06	0.000161	CcSEcCtD
Methotrexate—Vomiting—Cisplatin—lung cancer	5.01e-06	0.000161	CcSEcCtD
Methotrexate—Pruritus—Paclitaxel—lung cancer	5.01e-06	0.000161	CcSEcCtD
Methotrexate—Erythema multiforme—Doxorubicin—lung cancer	4.98e-06	0.00016	CcSEcCtD
Methotrexate—Rash—Cisplatin—lung cancer	4.97e-06	0.00016	CcSEcCtD
Methotrexate—Dermatitis—Cisplatin—lung cancer	4.96e-06	0.00016	CcSEcCtD
Methotrexate—Feeling abnormal—Docetaxel—lung cancer	4.94e-06	0.000159	CcSEcCtD
Methotrexate—Diarrhoea—Etoposide—lung cancer	4.94e-06	0.000159	CcSEcCtD
Methotrexate—Eye disorder—Doxorubicin—lung cancer	4.93e-06	0.000158	CcSEcCtD
Methotrexate—Tinnitus—Doxorubicin—lung cancer	4.91e-06	0.000158	CcSEcCtD
Methotrexate—Gastrointestinal pain—Docetaxel—lung cancer	4.91e-06	0.000158	CcSEcCtD
Methotrexate—Cardiac disorder—Doxorubicin—lung cancer	4.89e-06	0.000157	CcSEcCtD
Methotrexate—Diarrhoea—Paclitaxel—lung cancer	4.84e-06	0.000156	CcSEcCtD
Methotrexate—Angiopathy—Doxorubicin—lung cancer	4.78e-06	0.000154	CcSEcCtD
Methotrexate—Dizziness—Etoposide—lung cancer	4.77e-06	0.000153	CcSEcCtD
Methotrexate—Immune system disorder—Doxorubicin—lung cancer	4.76e-06	0.000153	CcSEcCtD
Methotrexate—Mediastinal disorder—Doxorubicin—lung cancer	4.75e-06	0.000153	CcSEcCtD
Methotrexate—Body temperature increased—Docetaxel—lung cancer	4.74e-06	0.000152	CcSEcCtD
Methotrexate—Abdominal pain—Docetaxel—lung cancer	4.74e-06	0.000152	CcSEcCtD
Methotrexate—Chills—Doxorubicin—lung cancer	4.73e-06	0.000152	CcSEcCtD
Methotrexate—Dizziness—Paclitaxel—lung cancer	4.68e-06	0.00015	CcSEcCtD
Methotrexate—Nausea—Cisplatin—lung cancer	4.68e-06	0.00015	CcSEcCtD
Methotrexate—Alopecia—Doxorubicin—lung cancer	4.66e-06	0.00015	CcSEcCtD
Methotrexate—Mental disorder—Doxorubicin—lung cancer	4.62e-06	0.000148	CcSEcCtD
Methotrexate—Vomiting—Etoposide—lung cancer	4.59e-06	0.000147	CcSEcCtD
Methotrexate—Erythema—Doxorubicin—lung cancer	4.59e-06	0.000147	CcSEcCtD
Methotrexate—Malnutrition—Doxorubicin—lung cancer	4.59e-06	0.000147	CcSEcCtD
Methotrexate—Rash—Etoposide—lung cancer	4.55e-06	0.000146	CcSEcCtD
Methotrexate—Dermatitis—Etoposide—lung cancer	4.55e-06	0.000146	CcSEcCtD
Methotrexate—Headache—Etoposide—lung cancer	4.52e-06	0.000145	CcSEcCtD
Methotrexate—Vomiting—Paclitaxel—lung cancer	4.5e-06	0.000145	CcSEcCtD
Methotrexate—Dysgeusia—Doxorubicin—lung cancer	4.49e-06	0.000144	CcSEcCtD
Methotrexate—Rash—Paclitaxel—lung cancer	4.46e-06	0.000143	CcSEcCtD
Methotrexate—Dermatitis—Paclitaxel—lung cancer	4.46e-06	0.000143	CcSEcCtD
Methotrexate—Back pain—Doxorubicin—lung cancer	4.44e-06	0.000143	CcSEcCtD
Methotrexate—Headache—Paclitaxel—lung cancer	4.43e-06	0.000142	CcSEcCtD
Methotrexate—Hypersensitivity—Docetaxel—lung cancer	4.42e-06	0.000142	CcSEcCtD
Methotrexate—Vision blurred—Doxorubicin—lung cancer	4.32e-06	0.000139	CcSEcCtD
Methotrexate—Asthenia—Docetaxel—lung cancer	4.31e-06	0.000138	CcSEcCtD
Methotrexate—Nausea—Etoposide—lung cancer	4.29e-06	0.000138	CcSEcCtD
Methotrexate—Ill-defined disorder—Doxorubicin—lung cancer	4.26e-06	0.000137	CcSEcCtD
Methotrexate—Pruritus—Docetaxel—lung cancer	4.25e-06	0.000136	CcSEcCtD
Methotrexate—Anaemia—Doxorubicin—lung cancer	4.24e-06	0.000136	CcSEcCtD
Methotrexate—Nausea—Paclitaxel—lung cancer	4.21e-06	0.000135	CcSEcCtD
Methotrexate—Malaise—Doxorubicin—lung cancer	4.14e-06	0.000133	CcSEcCtD
Methotrexate—Vertigo—Doxorubicin—lung cancer	4.12e-06	0.000132	CcSEcCtD
Methotrexate—Leukopenia—Doxorubicin—lung cancer	4.11e-06	0.000132	CcSEcCtD
Methotrexate—Diarrhoea—Docetaxel—lung cancer	4.11e-06	0.000132	CcSEcCtD
Methotrexate—Cough—Doxorubicin—lung cancer	4e-06	0.000129	CcSEcCtD
Methotrexate—Convulsion—Doxorubicin—lung cancer	3.98e-06	0.000128	CcSEcCtD
Methotrexate—Dizziness—Docetaxel—lung cancer	3.97e-06	0.000127	CcSEcCtD
Methotrexate—Myalgia—Doxorubicin—lung cancer	3.91e-06	0.000126	CcSEcCtD
Methotrexate—Arthralgia—Doxorubicin—lung cancer	3.91e-06	0.000126	CcSEcCtD
Methotrexate—Chest pain—Doxorubicin—lung cancer	3.91e-06	0.000126	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	3.88e-06	0.000125	CcSEcCtD
Methotrexate—Discomfort—Doxorubicin—lung cancer	3.86e-06	0.000124	CcSEcCtD
Methotrexate—Vomiting—Docetaxel—lung cancer	3.82e-06	0.000123	CcSEcCtD
Methotrexate—Rash—Docetaxel—lung cancer	3.78e-06	0.000122	CcSEcCtD
Methotrexate—Dermatitis—Docetaxel—lung cancer	3.78e-06	0.000121	CcSEcCtD
Methotrexate—Confusional state—Doxorubicin—lung cancer	3.78e-06	0.000121	CcSEcCtD
Methotrexate—Headache—Docetaxel—lung cancer	3.76e-06	0.000121	CcSEcCtD
Methotrexate—Anaphylactic shock—Doxorubicin—lung cancer	3.74e-06	0.00012	CcSEcCtD
Methotrexate—Infection—Doxorubicin—lung cancer	3.72e-06	0.00012	CcSEcCtD
Methotrexate—Nervous system disorder—Doxorubicin—lung cancer	3.67e-06	0.000118	CcSEcCtD
Methotrexate—Thrombocytopenia—Doxorubicin—lung cancer	3.67e-06	0.000118	CcSEcCtD
Methotrexate—Skin disorder—Doxorubicin—lung cancer	3.64e-06	0.000117	CcSEcCtD
Methotrexate—Hyperhidrosis—Doxorubicin—lung cancer	3.62e-06	0.000116	CcSEcCtD
Methotrexate—Anorexia—Doxorubicin—lung cancer	3.57e-06	0.000115	CcSEcCtD
Methotrexate—Nausea—Docetaxel—lung cancer	3.56e-06	0.000115	CcSEcCtD
Methotrexate—Hypotension—Doxorubicin—lung cancer	3.5e-06	0.000112	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Doxorubicin—lung cancer	3.41e-06	0.00011	CcSEcCtD
Methotrexate—Insomnia—Doxorubicin—lung cancer	3.39e-06	0.000109	CcSEcCtD
Methotrexate—Paraesthesia—Doxorubicin—lung cancer	3.36e-06	0.000108	CcSEcCtD
Methotrexate—Dyspnoea—Doxorubicin—lung cancer	3.34e-06	0.000107	CcSEcCtD
Methotrexate—Somnolence—Doxorubicin—lung cancer	3.33e-06	0.000107	CcSEcCtD
Methotrexate—Dyspepsia—Doxorubicin—lung cancer	3.3e-06	0.000106	CcSEcCtD
Methotrexate—Decreased appetite—Doxorubicin—lung cancer	3.26e-06	0.000105	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Doxorubicin—lung cancer	3.23e-06	0.000104	CcSEcCtD
Methotrexate—Fatigue—Doxorubicin—lung cancer	3.23e-06	0.000104	CcSEcCtD
Methotrexate—Pain—Doxorubicin—lung cancer	3.2e-06	0.000103	CcSEcCtD
Methotrexate—Feeling abnormal—Doxorubicin—lung cancer	3.09e-06	9.92e-05	CcSEcCtD
Methotrexate—Gastrointestinal pain—Doxorubicin—lung cancer	3.06e-06	9.84e-05	CcSEcCtD
Methotrexate—Urticaria—Doxorubicin—lung cancer	2.98e-06	9.56e-05	CcSEcCtD
Methotrexate—Body temperature increased—Doxorubicin—lung cancer	2.96e-06	9.51e-05	CcSEcCtD
Methotrexate—Abdominal pain—Doxorubicin—lung cancer	2.96e-06	9.51e-05	CcSEcCtD
Methotrexate—Hypersensitivity—Doxorubicin—lung cancer	2.76e-06	8.86e-05	CcSEcCtD
Methotrexate—Asthenia—Doxorubicin—lung cancer	2.69e-06	8.63e-05	CcSEcCtD
Methotrexate—Pruritus—Doxorubicin—lung cancer	2.65e-06	8.51e-05	CcSEcCtD
Methotrexate—Diarrhoea—Doxorubicin—lung cancer	2.56e-06	8.23e-05	CcSEcCtD
Methotrexate—Dizziness—Doxorubicin—lung cancer	2.48e-06	7.96e-05	CcSEcCtD
Methotrexate—Vomiting—Doxorubicin—lung cancer	2.38e-06	7.65e-05	CcSEcCtD
Methotrexate—Rash—Doxorubicin—lung cancer	2.36e-06	7.59e-05	CcSEcCtD
Methotrexate—Dermatitis—Doxorubicin—lung cancer	2.36e-06	7.58e-05	CcSEcCtD
Methotrexate—Headache—Doxorubicin—lung cancer	2.35e-06	7.54e-05	CcSEcCtD
Methotrexate—Nausea—Doxorubicin—lung cancer	2.22e-06	7.15e-05	CcSEcCtD
Methotrexate—ABCG2—Metabolism—CAT—lung cancer	6.18e-07	3.05e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—lung cancer	6.16e-07	3.04e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—lung cancer	6.15e-07	3.04e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—NRAS—lung cancer	6.14e-07	3.03e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CD—lung cancer	6.13e-07	3.02e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—CREBBP—lung cancer	6.12e-07	3.02e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NCOA3—lung cancer	6.11e-07	3.02e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CB—lung cancer	6.08e-07	3e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—ALB—lung cancer	6.05e-07	2.99e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—EP300—lung cancer	6.04e-07	2.98e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—lung cancer	6.02e-07	2.97e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ABCB1—lung cancer	6.02e-07	2.97e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—UGT1A1—lung cancer	6.01e-07	2.97e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—lung cancer	6.01e-07	2.97e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—APOA1—lung cancer	6e-07	2.96e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—POMC—lung cancer	5.99e-07	2.95e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—lung cancer	5.98e-07	2.95e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CYP1A1—lung cancer	5.98e-07	2.95e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—lung cancer	5.95e-07	2.94e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCG2—lung cancer	5.95e-07	2.94e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ADCY1—lung cancer	5.95e-07	2.94e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ERCC2—lung cancer	5.93e-07	2.93e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—TYMS—lung cancer	5.91e-07	2.92e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—lung cancer	5.89e-07	2.91e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APC—lung cancer	5.88e-07	2.9e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KIT—lung cancer	5.88e-07	2.9e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MAPK3—lung cancer	5.88e-07	2.9e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTM1—lung cancer	5.84e-07	2.88e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—HPGDS—lung cancer	5.83e-07	2.88e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO2—lung cancer	5.83e-07	2.88e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CREBBP—lung cancer	5.83e-07	2.88e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CB—lung cancer	5.82e-07	2.87e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGF—lung cancer	5.82e-07	2.87e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—lung cancer	5.81e-07	2.87e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CD—lung cancer	5.8e-07	2.86e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPP2R1B—lung cancer	5.8e-07	2.86e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GNG11—lung cancer	5.8e-07	2.86e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—lung cancer	5.77e-07	2.85e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—lung cancer	5.77e-07	2.85e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.74e-07	2.84e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—lung cancer	5.72e-07	2.82e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—POMC—lung cancer	5.72e-07	2.82e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—lung cancer	5.7e-07	2.81e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—lung cancer	5.67e-07	2.8e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTT1—lung cancer	5.66e-07	2.79e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—lung cancer	5.6e-07	2.76e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2A6—lung cancer	5.59e-07	2.76e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GCLC—lung cancer	5.59e-07	2.76e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CREBBP—lung cancer	5.57e-07	2.75e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—lung cancer	5.57e-07	2.75e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CYP1A1—lung cancer	5.54e-07	2.73e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BRAF—lung cancer	5.53e-07	2.73e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CD—lung cancer	5.53e-07	2.73e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALDOA—lung cancer	5.52e-07	2.72e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—EP300—lung cancer	5.5e-07	2.71e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ERCC2—lung cancer	5.49e-07	2.71e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—APOA1—lung cancer	5.48e-07	2.71e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CG—lung cancer	5.48e-07	2.7e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—lung cancer	5.47e-07	2.7e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6R—lung cancer	5.46e-07	2.7e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—ALB—lung cancer	5.46e-07	2.69e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CREBBP—lung cancer	5.46e-07	2.69e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—APOA1—lung cancer	5.4e-07	2.66e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOA3—lung cancer	5.36e-07	2.64e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CB—lung cancer	5.34e-07	2.64e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—lung cancer	5.34e-07	2.63e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ENO1—lung cancer	5.3e-07	2.62e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—CREBBP—lung cancer	5.3e-07	2.61e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—lung cancer	5.29e-07	2.61e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—lung cancer	5.29e-07	2.61e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—lung cancer	5.28e-07	2.61e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—lung cancer	5.25e-07	2.59e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—POMC—lung cancer	5.21e-07	2.57e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ADCY1—lung cancer	5.21e-07	2.57e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ABCG2—lung cancer	5.21e-07	2.57e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAP2K1—lung cancer	5.21e-07	2.57e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—RAF1—lung cancer	5.18e-07	2.56e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CD—lung cancer	5.17e-07	2.55e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.17e-07	2.55e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—APOA1—lung cancer	5.13e-07	2.53e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—HPGDS—lung cancer	5.11e-07	2.52e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO2—lung cancer	5.11e-07	2.52e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPP2R1B—lung cancer	5.08e-07	2.51e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CREBBP—lung cancer	5.08e-07	2.51e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CB—lung cancer	5.06e-07	2.5e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—HRAS—lung cancer	5.06e-07	2.5e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—lung cancer	5.03e-07	2.48e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—EP300—lung cancer	5.01e-07	2.47e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTT1—lung cancer	4.96e-07	2.45e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—HRAS—lung cancer	4.94e-07	2.44e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CG—lung cancer	4.93e-07	2.43e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	4.91e-07	2.42e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GCLC—lung cancer	4.9e-07	2.42e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2A6—lung cancer	4.9e-07	2.42e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—lung cancer	4.89e-07	2.41e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—lung cancer	4.86e-07	2.4e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—IL6—lung cancer	4.84e-07	2.39e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CB—lung cancer	4.82e-07	2.38e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CD—lung cancer	4.81e-07	2.38e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—lung cancer	4.81e-07	2.37e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—EP300—lung cancer	4.8e-07	2.37e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—lung cancer	4.78e-07	2.36e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2E1—lung cancer	4.75e-07	2.35e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—ALB—lung cancer	4.75e-07	2.35e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—APOA1—lung cancer	4.75e-07	2.34e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—IL6—lung cancer	4.73e-07	2.33e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NQO1—lung cancer	4.7e-07	2.32e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—POMC—lung cancer	4.69e-07	2.32e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CG—lung cancer	4.68e-07	2.31e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ENO1—lung cancer	4.64e-07	2.29e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—lung cancer	4.64e-07	2.29e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—CREBBP—lung cancer	4.64e-07	2.29e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MDM2—lung cancer	4.63e-07	2.29e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RAF1—lung cancer	4.62e-07	2.28e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—lung cancer	4.62e-07	2.28e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—lung cancer	4.6e-07	2.27e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—lung cancer	4.58e-07	2.26e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CREBBP—lung cancer	4.57e-07	2.26e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB2—lung cancer	4.57e-07	2.26e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—lung cancer	4.56e-07	2.25e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MTOR—lung cancer	4.51e-07	2.23e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CB—lung cancer	4.51e-07	2.23e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD4—lung cancer	4.5e-07	2.22e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—HRAS—lung cancer	4.49e-07	2.22e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—RAF1—lung cancer	4.48e-07	2.21e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—lung cancer	4.47e-07	2.21e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—lung cancer	4.47e-07	2.21e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—lung cancer	4.47e-07	2.2e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—POMC—lung cancer	4.46e-07	2.2e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—EP300—lung cancer	4.4e-07	2.17e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—lung cancer	4.36e-07	2.15e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—ALB—lung cancer	4.34e-07	2.14e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CREBBP—lung cancer	4.34e-07	2.14e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CG—lung cancer	4.34e-07	2.14e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CD—lung cancer	4.33e-07	2.14e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—IL6—lung cancer	4.3e-07	2.12e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—ALB—lung cancer	4.28e-07	2.11e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—STK11—lung cancer	4.24e-07	2.09e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CB—lung cancer	4.2e-07	2.07e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—EP300—lung cancer	4.17e-07	2.06e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2E1—lung cancer	4.17e-07	2.06e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—lung cancer	4.16e-07	2.06e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—lung cancer	4.16e-07	2.05e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—POMC—lung cancer	4.13e-07	2.04e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NQO1—lung cancer	4.12e-07	2.03e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CD—lung cancer	4.12e-07	2.03e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—lung cancer	4.07e-07	2.01e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—ALB—lung cancer	4.06e-07	2.01e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—SRC—lung cancer	4.05e-07	2e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CREBBP—lung cancer	4.02e-07	1.98e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—lung cancer	3.98e-07	1.96e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—EP300—lung cancer	3.97e-07	1.96e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—lung cancer	3.97e-07	1.96e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—lung cancer	3.95e-07	1.95e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—RAF1—lung cancer	3.93e-07	1.94e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTP1—lung cancer	3.92e-07	1.94e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CDKN1A—lung cancer	3.91e-07	1.93e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—NRAS—lung cancer	3.9e-07	1.92e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—lung cancer	3.9e-07	1.92e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CAT—lung cancer	3.82e-07	1.88e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CD—lung cancer	3.81e-07	1.88e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—EP300—lung cancer	3.79e-07	1.87e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CB—lung cancer	3.78e-07	1.86e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—ALB—lung cancer	3.76e-07	1.86e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—lung cancer	3.74e-07	1.85e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—lung cancer	3.74e-07	1.85e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—MAPK3—lung cancer	3.73e-07	1.84e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EP300—lung cancer	3.72e-07	1.83e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—STK11—lung cancer	3.71e-07	1.83e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ABCB1—lung cancer	3.71e-07	1.83e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—lung cancer	3.7e-07	1.83e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—lung cancer	3.65e-07	1.8e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—TYMS—lung cancer	3.65e-07	1.8e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—lung cancer	3.63e-07	1.79e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—SRC—lung cancer	3.61e-07	1.78e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTM1—lung cancer	3.6e-07	1.78e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CB—lung cancer	3.59e-07	1.77e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—lung cancer	3.56e-07	1.75e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—lung cancer	3.55e-07	1.75e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—lung cancer	3.48e-07	1.72e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NRAS—lung cancer	3.48e-07	1.72e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—EP300—lung cancer	3.46e-07	1.71e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTP1—lung cancer	3.44e-07	1.7e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP1A1—lung cancer	3.42e-07	1.69e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—ERCC2—lung cancer	3.39e-07	1.67e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—lung cancer	3.36e-07	1.66e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CAT—lung cancer	3.34e-07	1.65e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MAPK3—lung cancer	3.33e-07	1.64e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—lung cancer	3.32e-07	1.64e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CB—lung cancer	3.32e-07	1.64e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—lung cancer	3.29e-07	1.62e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—lung cancer	3.26e-07	1.61e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—lung cancer	3.26e-07	1.61e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—lung cancer	3.24e-07	1.6e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—TYMS—lung cancer	3.19e-07	1.58e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—lung cancer	3.17e-07	1.56e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTM1—lung cancer	3.16e-07	1.56e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—EP300—lung cancer	3.11e-07	1.54e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—lung cancer	3.1e-07	1.53e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—lung cancer	3.08e-07	1.52e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—lung cancer	3.03e-07	1.49e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP1A1—lung cancer	2.99e-07	1.48e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—lung cancer	2.99e-07	1.48e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—lung cancer	2.98e-07	1.47e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ERCC2—lung cancer	2.97e-07	1.47e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—EP300—lung cancer	2.96e-07	1.46e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—lung cancer	2.94e-07	1.45e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—APOA1—lung cancer	2.93e-07	1.45e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—lung cancer	2.9e-07	1.43e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—lung cancer	2.87e-07	1.42e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—HRAS—lung cancer	2.85e-07	1.41e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	2.81e-07	1.39e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—lung cancer	2.75e-07	1.36e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—EP300—lung cancer	2.74e-07	1.35e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CG—lung cancer	2.68e-07	1.32e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—lung cancer	2.66e-07	1.31e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—APOA1—lung cancer	2.57e-07	1.27e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—lung cancer	2.56e-07	1.26e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—POMC—lung cancer	2.55e-07	1.26e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HRAS—lung cancer	2.54e-07	1.26e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—lung cancer	2.52e-07	1.24e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CREBBP—lung cancer	2.48e-07	1.22e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—IL6—lung cancer	2.43e-07	1.2e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—lung cancer	2.4e-07	1.18e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CD—lung cancer	2.35e-07	1.16e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CG—lung cancer	2.34e-07	1.16e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—lung cancer	2.3e-07	1.14e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—lung cancer	2.25e-07	1.11e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—POMC—lung cancer	2.23e-07	1.1e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—lung cancer	2.19e-07	1.08e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CREBBP—lung cancer	2.17e-07	1.07e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—lung cancer	2.09e-07	1.03e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CD—lung cancer	2.06e-07	1.02e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CB—lung cancer	2.05e-07	1.01e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—ALB—lung cancer	2.03e-07	1e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—lung cancer	2.03e-07	1e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—lung cancer	2.03e-07	1e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—lung cancer	1.88e-07	9.28e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CB—lung cancer	1.8e-07	8.87e-06	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—lung cancer	1.79e-07	8.82e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—lung cancer	1.78e-07	8.79e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—lung cancer	1.77e-07	8.74e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—EP300—lung cancer	1.69e-07	8.34e-06	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—lung cancer	1.65e-07	8.17e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—lung cancer	1.55e-07	7.66e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—EP300—lung cancer	1.48e-07	7.31e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—lung cancer	1.25e-07	6.17e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—lung cancer	1.1e-07	5.41e-06	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—lung cancer	1.02e-07	5.04e-06	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—lung cancer	8.95e-08	4.42e-06	CbGpPWpGaD
